

PRIOR AUTHORIZATION POLICY

POLICY: Oncology (Other) – Jelmyto Prior Authorization Policy

- Jelmyto™ (mitomycin solution for pyelocalyceal administration – UroGen Pharma)

REVIEW DATE: 05/12/2021

OVERVIEW

Jelmyto, an alkylating agent, is indicated for the treatment of adults with low-grade upper tract **urothelial cancer**.¹

Dosing Information

Jelmyto is for pyelocalyceal use only.¹ The recommended dose is 4 mg/mL of mitomycin administered by ureteral catheter or a nephrostomy tube, with total instillation volume determined on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin). The dose is instilled once weekly for 6 weeks and in patients with a complete response 3 months after initiating Jelmyto, therapy can continue once a month for an additional 11 instillations.

Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines for Bladder Cancer (version 3.2021 – April 22, 2021) recommend Jelmyto as a primary treatment for upper urinary tract tumors.^{2,3} Jelmyto is recommended following complete or near complete endoscopic resection or ablation of a low-grade, low volume, solitary tumor in patients not a candidate for or seeking definitive treatment with nephroureterectomy.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Jelmyto. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Jelmyto as well as the monitoring required for adverse events and long-term efficacy, approval requires Jelmyto to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Jelmyto is recommended in those who meet the following criteria:

FDA-Approved Indications

- 1. Upper Tract Urothelial Cancer, Low-Grade.** Approve for 1 year if the patient meets the following criteria (A, B, C, and D):
 - A) The patient is ≥ 18 years of age; AND
 - B) The patient has non-metastatic disease; AND
 - C) The patient has undergone endoscopic resection or ablation; AND
 - D) Jelmyto is prescribed by or in consultation with an oncologist or urologist.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Jelmyto is not recommended in the following situations.

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Jelmyto™ for pyelocalyceal solution [prescribing information]. Princeton, NJ: UroGen Pharma; January 2021.
2. The NCCN Bladder Cancer Clinical Practice Guidelines in Oncology (Version 3.2021 – April 22, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed May 6, 2021.
3. The NCCN Drugs and Biologics Compendium. © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on May 6, 2021. Search term: Jelmyto.